Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria.

Literature DB >> 19881520

Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria.

Abstract

Plasmodium falciparum resistance to chloroquine and sulphadoxine-pyrimethamine has led to the recent adoption of artemisinin-based combination therapies (ACTs) as the first line of treatment against malaria. ACTs comprise semisynthetic artemisinin derivatives paired with distinct chemical classes of longer acting drugs. These artemisinins are exceptionally potent against the pathogenic asexual blood stages of Plasmodium parasites and also act on the transmissible sexual stages. These combinations increase the rates of clinical and parasitological cures and decrease the selection pressure for the emergence of antimalarial resistance. This Review article discusses our current knowledge about the mode of action of ACTs, their pharmacological properties and the proposed mechanisms of drug resistance.

Entities: Chemical Disease Gene Mutation Species

Mesh：

Substances：

Year: 2009 PMID： 19881520 PMCID： PMC2901398 DOI： 10.1038/nrmicro2239

Source DB: PubMed Journal: Nat Rev Microbiol ISSN： 1740-1526 Impact factor: 60.633

138 in total

Review 1. Combination therapy for malaria in Africa: hype or hope?

Authors: P B Bloland; M Ettling; S Meek
Journal: Bull World Health Organ Date: 2003-11-17 Impact factor: 9.408

2. Expansion of wild type allele rather than back mutation in pfcrt explains the recent recovery of chloroquine sensitivity of Plasmodium falciparum in Malawi.

Authors: Toshihiro Mita; Akira Kaneko; Jeffery K Lum; Innocent L Zungu; Takahiro Tsukahara; Hideaki Eto; Takatoshi Kobayakawa; Anders Björkman; Kazuyuki Tanabe
Journal: Mol Biochem Parasitol Date: 2004-05 Impact factor: 1.759

3. Metabolism-dependent neutrophil cytotoxicity of amodiaquine: A comparison with pyronaridine and related antimalarial drugs.

Authors: D J Naisbitt; D P Williams; P M O'Neill; J L Maggs; D J Willock; M Pirmohamed; B K Park
Journal: Chem Res Toxicol Date: 1998-12 Impact factor: 3.739

4. Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients.

Authors: F Ezzet; R Mull; J Karbwang
Journal: Br J Clin Pharmacol Date: 1998-12 Impact factor: 4.335

5. Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.

Authors: D Schellenberg; C Menendez; E Kahigwa; J Aponte; J Vidal; M Tanner; H Mshinda; P Alonso
Journal: Lancet Date: 2001-05-12 Impact factor: 79.321

6. A molecular marker for chloroquine-resistant falciparum malaria.

Authors: A Djimdé; O K Doumbo; J F Cortese; K Kayentao; S Doumbo; Y Diourté; D Coulibaly; A Dicko; X Z Su; T Nomura; D A Fidock; T E Wellems; C V Plowe
Journal: N Engl J Med Date: 2001-01-25 Impact factor: 91.245

Review 7. Possible modes of action of the artemisinin-type compounds.

Authors: P L Olliaro; R K Haynes; B Meunier; Y Yuthavong
Journal: Trends Parasitol Date: 2001-03

8. Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial.

Authors: Tinh Hien Tran; Christiane Dolecek; Phuong Mai Pham; Thi Dung Nguyen; Thanh Truong Nguyen; Hong Thai Le; Thi Hoai An Dong; Tan Thanh Tran; Kasia Stepniewska; Nicholas J White; Jeremy Farrar
Journal: Lancet Date: 2004-01-03 Impact factor: 79.321

9. Safety evaluation of fixed combination piperaquine plus dihydroartemisinin (Artekin) in Cambodian children and adults with malaria.

Authors: Harin Karunajeewa; Chiv Lim; Te-Yu Hung; Kenneth F Ilett; Mey Bouth Denis; Doung Socheat; Timothy M E Davis
Journal: Br J Clin Pharmacol Date: 2004-01 Impact factor: 4.335

Review 10. Ferriprotoporphyrin IX, phospholipids, and the antimalarial actions of quinoline drugs.

Authors: Coy D Fitch
Journal: Life Sci Date: 2004-03-05 Impact factor: 5.037

183 in total

Review 1. Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic.

Authors: Benjamin Blasco; Didier Leroy; David A Fidock
Journal: Nat Med Date: 2017-08-04 Impact factor: 53.440

2. Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice.

Authors: Ramesh Gujjar; Farah El Mazouni; Karen L White; John White; Sharon Creason; David M Shackleford; Xiaoyi Deng; William N Charman; Ian Bathurst; Jeremy Burrows; David M Floyd; David Matthews; Frederick S Buckner; Susan A Charman; Margaret A Phillips; Pradipsinh K Rathod
Journal: J Med Chem Date: 2011-05-12 Impact factor: 7.446

3. Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue.

Authors: Sophie H Adjalley; Geoffrey L Johnston; Tao Li; Richard T Eastman; Eric H Ekland; Abraham G Eappen; Adam Richman; B Kim Lee Sim; Marcus C S Lee; Stephen L Hoffman; David A Fidock
Journal: Proc Natl Acad Sci U S A Date: 2011-10-31 Impact factor: 11.205

4. Drug discovery: Priming the antimalarial pipeline.

Authors: David A Fidock
Journal: Nature Date: 2010-05-20 Impact factor: 49.962

5. Spontaneous mutations in the Plasmodium falciparum sarcoplasmic/ endoplasmic reticulum Ca2+-ATPase (PfATP6) gene among geographically widespread parasite populations unexposed to artemisinin-based combination therapies.

Authors: Kazuyuki Tanabe; Sedigheh Zakeri; Nirianne Marie Q Palacpac; Manada Afsharpad; Milijaona Randrianarivelojosia; Akira Kaneko; Aung Swi Prue Marma; Toshihiro Horii; Toshihiro Mita
Journal: Antimicrob Agents Chemother Date: 2010-10-18 Impact factor: 5.191